92 related articles for article (PubMed ID: 11739539)
1. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into human MHC-II association with invariant chain.
Wang N; Waghray D; Caveney NA; Jude KM; Garcia KC
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2403031121. PubMed ID: 38687785
[TBL] [Abstract][Full Text] [Related]
3. A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules.
Rötzschke O; Lau JM; Hofstätter M; Falk K; Strominger JL
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):16946-50. PubMed ID: 12471156
[TBL] [Abstract][Full Text] [Related]
4. A novel family of human leukocyte antigen class II receptors may have its origin in archaic human species.
Temme S; Zacharias M; Neumann J; Wohlfromm S; König A; Temme N; Springer S; Trowsdale J; Koch N
J Biol Chem; 2014 Jan; 289(2):639-53. PubMed ID: 24214983
[TBL] [Abstract][Full Text] [Related]
5. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes.
Greenbaum J; Sidney J; Chung J; Brander C; Peters B; Sette A
Immunogenetics; 2011 Jun; 63(6):325-35. PubMed ID: 21305276
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR expression in B-lymphocytes in vitro is not suppressed by the absence of exogenous antigens.
Park JH; Lee YJ; Na SY; Cho EW; Kim KL
Mol Cells; 2001 Oct; 12(2):164-72. PubMed ID: 11710516
[TBL] [Abstract][Full Text] [Related]
7. Abatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles.
Long SA; Muir VS; Jones BE; Wall VZ; Ylescupidez A; Hocking AM; Pribitzer S; Thorpe J; Fuchs B; Wiedeman AE; Tatum M; Lambert K; Uchtenhagen H; Speake C; Ng B; Heubeck AT; Torgerson TR; Savage AK; Maldonado MA; Ray N; Khaychuk V; Liu J; Linsley PS; Buckner JH
Front Immunol; 2024; 15():1383110. PubMed ID: 38650930
[TBL] [Abstract][Full Text] [Related]
8. Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis.
Sugiyama N; Terry FE; Gutierrez AH; Hirano T; Hoshi M; Mizuno Y; Martin W; Yasunaga S; Niiro H; Fujio K; De Groot AS
Front Immunol; 2024; 15():1377911. PubMed ID: 38812524
[TBL] [Abstract][Full Text] [Related]
9. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models.
Rosloniec EF; Brandstetter T; Leyer S; Schwaiger FW; Nagy ZA
J Autoimmun; 2006 Nov; 27(3):182-95. PubMed ID: 17081730
[TBL] [Abstract][Full Text] [Related]
10. Human Hepatitis B Viral Infection Outcomes Are Linked to Naturally Occurring Variants of
Graves AM; Virdis F; Morrison E; Álvaro-Benito M; Khan AA; Freund C; Golovkina TV; Denzin LK
J Immunol; 2020 Aug; 205(4):923-935. PubMed ID: 32690655
[TBL] [Abstract][Full Text] [Related]
11. Association of rheumatoid arthritis with HLA-DR1 and HLA-DR4 in Hungary.
Kapitány A; Zilahi E; Szántó S; Szücs G; Szabó Z; Végvári A; Rass P; Sipka S; Szegedi G; Szekanecz Z
Ann N Y Acad Sci; 2005 Jun; 1051():263-70. PubMed ID: 16126967
[TBL] [Abstract][Full Text] [Related]
12. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen.
Auger I; Sebbag M; Vincent C; Balandraud N; Guis S; Nogueira L; Svensson B; Cantagrel A; Serre G; Roudier J
Arthritis Rheum; 2005 Nov; 52(11):3424-32. PubMed ID: 16255019
[TBL] [Abstract][Full Text] [Related]
13. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II.
Dessen A; Lawrence CM; Cupo S; Zaller DM; Wiley DC
Immunity; 1997 Oct; 7(4):473-81. PubMed ID: 9354468
[TBL] [Abstract][Full Text] [Related]
14. Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.
Santambrogio L
Front Immunol; 2022; 13():878271. PubMed ID: 35651601
[TBL] [Abstract][Full Text] [Related]
15. Tuning DO:DM Ratios Modulates MHC Class II Immunopeptidomes.
Olsson N; Jiang W; Adler LN; Mellins ED; Elias JE
Mol Cell Proteomics; 2022 Mar; 21(3):100204. PubMed ID: 35085787
[TBL] [Abstract][Full Text] [Related]
16. Repertoire-scale determination of class II MHC peptide binding via yeast display improves antigen prediction.
Rappazzo CG; Huisman BD; Birnbaum ME
Nat Commun; 2020 Sep; 11(1):4414. PubMed ID: 32887877
[TBL] [Abstract][Full Text] [Related]
17. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications.
Busch R; Kollnberger S; Mellins ED
Nat Rev Rheumatol; 2019 Jun; 15(6):364-381. PubMed ID: 31092910
[TBL] [Abstract][Full Text] [Related]
18. Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity.
Ito Y; Ashenberg O; Pyrdol J; Luoma AM; Rozenblatt-Rosen O; Hofree M; Christian E; Ferrari de Andrade L; Tay RE; Teyton L; Regev A; Dougan SK; Wucherpfennig KW
J Exp Med; 2018 Oct; 215(10):2617-2635. PubMed ID: 30185635
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP
Anczurowski M; Yamashita Y; Nakatsugawa M; Ochi T; Kagoya Y; Guo T; Wang CH; Rahman MA; Saso K; Butler MO; Hirano N
Sci Rep; 2018 Mar; 8(1):4804. PubMed ID: 29555965
[TBL] [Abstract][Full Text] [Related]
20. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis.
Ting YT; Petersen J; Ramarathinam SH; Scally SW; Loh KL; Thomas R; Suri A; Baker DG; Purcell AW; Reid HH; Rossjohn J
J Biol Chem; 2018 Mar; 293(9):3236-3251. PubMed ID: 29317506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
